Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/13/2024 | $321.00 → $365.00 | In-line → Underperform | Evercore ISI | |
| 10/14/2024 | $349.00 → $332.00 | Equal-Weight → Underweight | Morgan Stanley | |
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo | |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic | |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan | |
| 6/28/2024 | Mkt Perform | Raymond James | ||
| 6/26/2024 | $380.00 | Buy | Citigroup | |
| 4/26/2024 | $338.00 → $340.00 | Buy | TD Cowen |
MCLEAN, Va., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced that Harish Nanda, the company's Chief Technology Officer, has been named a 2024 NVTC Tech100 Tech Executive honoree by the Northern Virginia Technology Council (NVTC). NVTC is one of the nation's largest technology councils, with a mission to establish the Northern Virginia region as a major global technology center. NVTC also recognized Acentra Health among Tech100 companies for driving innovation and supporting the region's economic growth.
Growth Driven By Solid Execution & Strength Across End Markets StandardAero (NYSE:SARO) announced results today for its third quarter ended September 30, 2024 ("Third Quarter 2024"). Third Quarter 2024 Highlights Revenue increased 13.2% year-over-year to $1,244.6 million Net Income was $16.4 million; Net Income Margin was 1.3% Adjusted EBITDA increased 26.0% year-over-year to $168.4 million Adjusted EBITDA Margin was 13.5%, an increase of 137 basis points compared to the prior year's quarter Capital expenditures were $25.3 million, reflecting continued investment in growth initiatives including the LEAP-1A/-1B program and the CFM56 Center of Excellence greenfield facility
MEMPHIS, Tenn., Nov. 12, 2024 /PRNewswire/ -- Sedgwick, a leading global provider of claims management, loss adjusting and technology-enabled business solutions, announced the closing of a significant minority investment in Sedgwick led by Altas Partners ("Altas"), a North American private equity firm, which was made public last month.Current investors, including funds managed by global investment firm Carlyle (NASDAQ:CG) and Stone Point Capital LLC, will remain as investors and continue to make significant new investments in the business, with Carlyle maintaining its control position in partnership with the investor group and the Sedgwick management team. Longtime investors CDPQ and Onex ar
SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)
SC 13G/A - CATERPILLAR INC (0000018230) (Subject)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
Nazzic Keene to Join the Board IRVING, Texas, Oct. 11, 2024 /PRNewswire/ -- Caterpillar Inc. (NYSE:CAT) today announced that Nazzic S. Keene, former chief executive officer of Science Applications International Corporation (SAIC), has been appointed to the Caterpillar board of directors, effective Nov. 1. Keene will serve on Caterpillar's Nominating & Governance Committee and Compensation & Human Resources Committee. "We are pleased to welcome a leader of such high caliber to our board," said Caterpillar Chairman and CEO Jim Umpleby. "With Nazzic's leadership history of drivi
Oct. 1, 2024-- ITT Inc. (NYSE:ITT) today announced the election of Maggie Chu to its Board of Directors. Ms. Chu currently serves as Chief Human Resources Officer of Littelfuse, Inc. (NASDAQ:LFUS), a global manufacturer of circuit protection and power control components serving customers across industrial, transportation and electronics end markets with a market capitalization of more than $6 billion. She has been with Littelfuse since 2021 and currently leads the company's human resources (HR) and corporate communications functions globally. Ms. Chu's appointment to the ITT board is effective immediately. "Maggie is an experienced and seasoned Human Resources executive with a robust track
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its third quarter ended September 30, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "We delivered consistent performance in the third quarter of 2024, capitalizing on increased new deal activity and the strength of our existing portfolio companies. With another strong quarter of originations, we benefited from access to the broader Carlyle Global Credit Platform, as we supplemented our core cash flow strategy with differentiated deal flow and specialty lending
Third-quarter 2024 profit per share of $5.06; adjusted profit per share of $5.17Enterprise operating cash flow was $3.6 billion in the third quarter of 2024Deployed $1.5 billion of cash for share repurchases and dividends in the third quarterThird Quarter ($ in billions except profit per share) 2024 2023 Sales and Revenues $16.1 $16.8 Profit Per Share $5.06 $5.45 Adjusted Profit Per Share $5.17 $5.52 Please see a reconciliation of GAAP to non-GAAP financial measures in the appendix on pages 13 and 14. IRVING, Texas, Oct. 30, 2024 /PRNewswire/ -- Caterpillar Inc. (NYSE:CAT) announced third-quarter 2024 results. Sales and revenues for the third quarter of 2024 were $16.1 billion, a 4% decrea
4 - CATERPILLAR INC (0000018230) (Issuer)
4 - CATERPILLAR INC (0000018230) (Issuer)
4 - CATERPILLAR INC (0000018230) (Issuer)
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
Directors Robert Langer and Stephen Berenson will also retire from the Board.
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
10-Q - Carlyle Group Inc. (0001527166) (Filer)
10-Q - CATERPILLAR INC (0000018230) (Filer)
4 - CATERPILLAR INC (0000018230) (Issuer)
4 - Carlyle Group Inc. (0001527166) (Issuer)
4 - CATERPILLAR INC (0000018230) (Issuer)
Evercore ISI downgraded Caterpillar from In-line to Underperform and set a new price target of $365.00 from $321.00 previously
Morgan Stanley downgraded Caterpillar from Equal-Weight to Underweight and set a new price target of $332.00 from $349.00 previously
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00